Stock assessment and management recommendations for Pacific sardine (Sardinops sagax) in 1997

The primary goal of sardine management as directed by the California Fish and Game Code is rehabilitation of the resource with an added objective of maximizing sustained harvest. Accordingly, the Code states that the annual sardine quota can be set at an amount greater than 1,000 tons, providing that the level of take allows for continued increase in the spawning population. We estimated the sardine population size to have been 464,000 short tons on July 1, 1997. Our estimate was based on output from a modified version of the integrated stock assessment model called CANSAR (Deriso et al. 1996). CANSAR is a forward-casting, age-structured analysis using fishery-dependent and fishery-independent data to obtain annual estimates of sardine abundance, year-class strength and age-specific fishing mortality for 1983 through the first semester of 1997. Non-linear least-squares criteria are used to find the best fit between model estimates and input data. Questions about stock structure and range extent remain major sources of uncertainty in assessing current sardine population biomass. Recent survey results and anecdotal evidence suggest increased sardine abundance in the Pacific Northwest and areas offshore from central and southern California. It is difficult to determine if those fish were part of the stock available to the California fishery. In an attempt to address this problem, the original CANSAR model was reconfigured into a Two-Area Migration Model (CANSAR-TAM) which accounted for sardine lost to the areas of the fishery and abundance surveys due to population expansion and net emigration. While the model includes guesses and major assumptions about net emigration and recruitment, it provides an estimate which is likely closer to biological reality than past assessments. The original CANSAR model was also used and estimates are provided for comparison. Based on the 1997 estimate of total biomass and the harvest formula used last year, we recommend a 1998 sardine harvest quota of 48,000 tons for the California fishery. The 1998 quota is a decrease of 11% from the final 1997 sardine harvest quota for California of 54,000 tons. (55pp.

In situ XRF and gamma ray spectrometer for Mars sample return mission

A combined in situ X-ray fluorescence (XRF) and passive gamma ray spectrometer instrument is proposed for the chemical elemental analysis of various Martian surfaces and samples. The combined instrument can be carried on board a rover. The passive gamma ray or the neutron excited gamma ray system would be used to determine the elemental composition of the Martian surface while the rover is in motion. The XRF system would be used to perform analysis either on the Martian surface or on collected samples when the rover is stationary. The latter function is important both in cataloging the collected samples and in the selection of samples to be returned to earth. For both systems, data accumulation time would be on the order of 30 minutes. No sample preparation would be necessary

Stock assessment of Pacific sardine for 1998 with management recommendations for 1999

The primary goal of sardine management as directed by the California Fish and Game Code is rehabilitation of the resource with an added objective of maximizing sustained harvest. Accordingly, the Code states that the annual sardine quota can be set at an amount greater than 1,000 tons, providing that the level of take allows for continued increase in the spawning population. We estimated the sardine population size within the range of the fishery and survey data (Ensenada, Baja California to San Francisco, California) to have been 1,182,881 short tons on July 1, 1998. Our estimate was based on output from a modified version of the integrated stock assessment model called CANSAR (Deriso et al. 1996). CANSAR is a forward-casting, age-structured analysis using fishery-dependent and fishery-independent data to obtain annual estimates of sardine abundance, year-class strength and age-specific fishing mortality for 1983 through the first semester of 1998. Non-linear least-squares criteria are used to find the best fit between model estimates and input data. Questions about stock structure and range extent remain major sources of uncertainty in assessing current sardine population biomass. Recent survey results and anecdotal evidence suggest increased sardine abundance in the Pacific Northwest and areas offshore from central and southern California. It is difficult to determine if those fish were part of the stock available to the California fishery. Last year, in an attempt to address this problem, the original CANSAR model was reconfigured into a Two-Area Migration Model (CANSAR-TAM; Hill et al. 1998) which accounted for sardine lost to the areas of the fishery and abundance surveys due to population expansion and net emigration. While the model includes guesses and major assumptions about net emigration and recruitment, it provides an estimate which is likely closer to biological reality than original CANSAR assessments. Corroborative results from a new, preliminary sardine stock assessment model, 'SAM', are also presented in this report. Based on the 1998 estimate of age 1+ biomass within the range of the fishery and survey data, and a proposed harvest formula in the draft Coastal Pelagic Species Fishery Management Plan (Amendment 8), we recommend a 1999 sardine harvest quota of 132,800 tons for the California fishery. The 1999 quota is a significant increase from the final 1998 sardine harvest quota for California of 48,000 tons. (93pp.

Chinese offshore oil production : Hopes and reality 【Report】

China started to develop its offshore oil resources in earnest in the early 1980s, when world oil pricewas high and projections about the potential of its offshore oil were extremely rosy. But as explorationand development efforts unfolded in the 1980s, disillusionment set in very quickly, given the mediocreamount of oil discoveries made. This article traces the development of the Chinese offshore oil industryfrom the early 1980s to 1998, with emphasis on the last ten years. Various aspects of development,including length of seismic survey lines undertaken, number of wells drilled, amount of oil discovered,amount of investments made, offshore fields developed, offshore production and revenue from oil salesare presented and analysed.Further, the article also discusses in detail the factors that contributed to the deflation of the highhopes relating to Chinese offshore production, with a final section taking a glimpse into the future

ACR Appropriateness Criteria® Spinal Bone Metastases

The spine is a common site of involvement in patients with bone metastases. Apart from pain, hypercalcemia, and pathologic fracture, progressive tumor can result in neurologic deterioration caused by spinal cord compression or cauda equina involvement. The treatment of spinal bone metastases depends on histology, site of disease, extent of epidural disease, extent of metastases elsewhere, and neurologic status. Treatment recommendations must weigh the risk-benefit profile of external beam radiation therapy (EBRT) for the particular individual's circumstance, including neurologic status, performance status, extent of spinal disease, stability of the spine, extra-spinal disease status, and life expectancy. Patients with spinal instability should be evaluated for surgical intervention. Research studies are needed that evaluate the combination or sequencing of localized therapies with systemic therapies including chemotherapy, hormonal therapy (HT), osteoclast inhibitors (OI), and radiopharmaceuticals. The roles of stereotactic body radiation therapy (SBRT) in the management of spinal oligometastasis, radioresistant spinal metastasis, and previously irradiated but progressive spinal metastasis are emerging, but more research is needed to validate the findings from retrospective studies. The American College of Radiology Appropriateness Criteria are evidence-based guidelines for specific clinical conditions that are reviewed every 2 years by a multidisciplinary expert panel. The guideline development and review include an extensive analysis of current medical literature from peer-reviewed journals and the application of a well-established consensus methodology (modified Delphi) to rate the appropriateness of imaging and treatment procedures by the panel. In those instances where evidence is lacking or not definitive, expert opinion may be used to recommend imaging or treatment.Peer Reviewedhttps://deepblue.lib.umich.edu/bitstream/2027.42/140115/1/jpm.2012.0376.pd

ACR Appropriateness Criteria® Non-Spine Bone Metastases

Abstract Bone is one of the most common sites of metastatic spread of malignancy, with possible deleterious effects including pain, hypercalcemia, and pathologic fracture. External beam radiotherapy (EBRT) remains the mainstay for treatment of painful bone metastases. EBRT may be combined with other local therapies like surgery or with systemic treatments like chemotherapy, hormonal therapy, osteoclast inhibitors, or radiopharmaceuticals. EBRT is not commonly recommended for patients with asymptomatic bone metastases unless they are associated with a risk of pathologic fracture. For those who do receive EBRT, appropriate fractionation schemes include 30?Gy in 10 fractions, 24?Gy in 6 fractions, 20?Gy in 5 fractions, or a single 8?Gy fraction. Single fraction treatment maximizes convenience, while fractionated treatment courses are associated with a lower incidence of retreatment. The appropriate postoperative dose fractionation following surgical stabilization is uncertain. Reirradiation with EBRT may be safe and provide pain relief, though retreatment might create side effect risks which warrant its use as part of a clinical trial. All patients with bone metastases should be considered for concurrent management by a palliative care team, with patients whose life expectancy is less than six months appropriate for hospice evaluation. The American College of Radiology Appropriateness Criteria are evidence-based guidelines for specific clinical conditions that are reviewed every two years by a multidisciplinary expert panel. The guideline development and review include an extensive analysis of current medical literature from peer reviewed journals and the application of a well-established consensus methodology (modified Delphi) to rate the appropriateness of imaging and treatment procedures by the panel. In those instances where evidence is lacking or not definitive, expert opinion may be used to recommend imaging or treatment.Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/98458/1/jpm%2E2011%2E0512.pd

Use of plasma DNA to predict mortality and need for intensive care in patients with abdominal pain

Background We investigated the value of plasma deoxyribonucleic acid concentrations in patients presenting with acute abdominal pain to predict need for intensive care or mortality. Methods Plasma deoxyribonucleic acid taken from patients with acute abdominal pain was analyzed for the β-globin gene using the quantitative polymerase chain reaction. The primary outcome measure was the combined 28-day mortality or admission to the intensive care unit. Results Of 287 consecutive patients with acute abdominal pain recruited, 12 patients were admitted to the intensive care unit and/or died. Median plasma DNA concentrations were higher in patients with cancer and major organ inflammation. Mean plasma DNA concentrations were three-fold higher in patients with systemic inflammatory response syndrome, five-fold higher in patients who died within 28 days, and eight-fold higher in patients admitted to the intensive care unit. The area under the receiver operator curve for plasma DNA concentrations and intensive care unit admission/mortality was 0.804. At a cut-off of 1100 GE/ml, the sensitivity was 67% (95%CI 35–90) and specificity was 89% (95%CI 84–92). At a cut-off of 175 GE/ml, the sensitivity was 100% (95%CI 73–100) and specificity was 30% (95%CI 25–36). Plasma DNA concentration predicted need for intensive care unit admission or death (adjusted odds ratio 1.4; P < 0.0001). Conclusions Plasma DNA may have a role in patients with acute abdominal pain as a marker for inflammation and cancer, and a predictor of intensive care unit admission/mortality

Hundreds of variants clustered in genomic loci and biological pathways affect human height

Most common human traits and diseases have a polygenic pattern of inheritance: DNA sequence variants at many genetic loci influence the phenotype. Genome-wide association (GWA) studies have identified more than 600 variants associated with human traits, but these typically explain small fractions of phenotypic variation, raising questions about the use of further studies. Here, using 183,727 individuals, we show that hundreds of genetic variants, in at least 180 loci, influence adult height, a highly heritable and classic polygenic trait. The large number of loci reveals patterns with important implications for genetic studies of common human diseases and traits. First, the 180 loci are not random, but instead are enriched for genes that are connected in biological pathways (P = 0.016) and that underlie skeletal growth defects (P < 0.001). Second, the likely causal gene is often located near the most strongly associated variant: in 13 of 21 loci containing a known skeletal growth gene, that gene was closest to the associated variant. Third, at least 19 loci have multiple independently associated variants, suggesting that allelic heterogeneity is a frequent feature of polygenic traits, that comprehensive explorations of already-discovered loci should discover additional variants and that an appreciable fraction of associated loci may have been identified. Fourth, associated variants are enriched for likely functional effects on genes, being over-represented among variants that alter amino-acid structure of proteins and expression levels of nearby genes. Our data explain approximately 10% of the phenotypic variation in height, and we estimate that unidentified common variants of similar effect sizes would increase this figure to approximately 16% of phenotypic variation (approximately 20% of heritable variation). Although additional approaches are needed to dissect the genetic architecture of polygenic human traits fully, our findings indicate that GWA studies can identify large numbers of loci that implicate biologically relevant genes and pathways.